CDC-RFA-CK-24-0002: Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCEZID notices from 2024.
Centers for Disease Control - NCEZID offered grants to the applicants described in the notice. It expected to make about 65 awards worth $240 million in total. Applications closed on April 30, 2024.
From the official notice on Grants.gov, last changed February 14, 2024. Checked November 7, 2026.
- Total funding$240 million
- Expected awards65
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 14, 2024 |
|---|---|
| Deadline | April 30, 2024 |
| Archived by Grants.gov | May 23, 2024 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
To maximize the impact of available funding, the ELC program has chosen to leverage the legislative authorities associated with this funding to limit recipients to those meeting the population thresholds described below. Working with recipients of sizeable populations allows ELC to take advantage of economy of scale in implementing programs and reducing the marginal cost of additional resources added per population served. This strategy allows ELC to reach the greatest number of people for its budget while also balancing the need for direct support to some of the United States’ largest cities and counties. Pursuant to 42 USC 300hh-31, eligible applicants include:The 51 State health departments or their bona fide agents, including the District of Columbia. Local health agencies or their bona fide agents, if they serve a city population of 1.5M or more (i.e., Chicago, Houston, New York City, Philadelphia). If the city does not have a public health department, then the county covering the jurisdiction may apply (i.e., Los Angeles, CA covered by Los Angeles County and Phoenix, AZ covered by Maricopa County).All US territories and affiliates in the Caribbean and Pacific (American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Puerto Rico, Republic of Palau, Republic of the Marshall Islands, and US Virgin Islands).*Population for county and city jurisdictions. Source: U.S. Census Bureau, Population Division - Annual Estimates of the Resident Population for Counties in the United States: April 1, 2020, to July 1, 2021 - Release Date: March 2022.
Is this a realistic fit?
- Most of the program's money (86% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Notice of Funding Opportunity (NOFO) builds upon the program that was initiated in 1995 as one of the key activities under CDC’s plan to address emerging infectious disease threats. The purpose of this NOFO is to protect the public health and safety of the American people by enhancing the capacity of public health agencies to effectively detect, respond, prevent and control known an emerging (or re-emerging) infectious diseases. This is accomplished by providing financial and technical resources to (1) strengthen epidemiologic capacity; (2) enhance laboratory capacity; (3) improve information systems; and (4) enhance collaboration among epidemiology, laboratory, and information systems components of public health departments.
Who has won Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) grants before
From fiscal 2021 to 2025, Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (93.323) awarded $31 billion across 300 grant awards, an average of $103 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Public Health Foundation Enterprises, Inc. | California | 3 | $2.9 billion |
| Department of State Health Services | Texas | 2 | $1.7 billion |
| Florida Department of Health | Florida | 2 | $1.4 billion |
| Health Research, Inc. | New York | 3 | $1.1 billion |
| Pennsylvania Department of Health | Pennsylvania | 2 | $1.1 billion |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK-24-0002 still open?
No. It closed on April 30, 2024.
Who can apply for Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)?
Centers for Disease Control - NCEZID accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)?
Closed April 30, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $240 million in total across about 65 awards.
Who has won Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) grants before?
The largest recipients over five fiscal years were Public Health Foundation Enterprises, Inc., Department of State Health Services, Florida Department of Health. The program made 300 awards worth $31 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)